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Background: Both high on-treatment platelet reactivity and periprocedural myocardial infarction (MI) are associated with adverse events following 
percutaneous coronary intervention (PCI). The optimal method of quantifying platelet reactivity remains controversial.
Methods: 98 patients underwent platelet function testing with VerifyNow P2Y12 at 6 to 24 hours following PCI; we anticipate 150 patients will be 
included in the final presentation of this data. All patients received 600 mg of clopidogrel before PCI; those presenting with acute MI or baseline 
troponin elevation were excluded. Periprocedural MI was defined as peak troponin >upper limit of normal (0.12 ng/mL), and high on-treatment 
platelet reactivity (HOPR) as ≥235 platelet reactivity units. Multivariable logistic regression was performed to assess the independent effect of on-
treatment platelet reactivity upon peak troponin.
Results: 25.5% of patients had HOPR following PCI. Peak troponin for patients with HOPR was 10.1 ng/mL, v. 0.63 ng/mL for patients without 
HOPR. Univariable analysis showed HOPR was associated with periprocedural MI (p=0.04). Following multivariable adjustment, HOPR remained 
significantly associated with periprocedural MI. (Table)
Conclusion: HOPR as measured by VerifyNow P2Y12 is associated with periprocedural MI. More aggressive P2Y12 inhibition of such patients may 
prevent periprocedural MI. 
Odds Ratio for Periprocedural MI 95% Confidence Interval p value
HOPR (PRU ≥235) 3.41 1.06-11.0 0.04
Congestive heart failure 2.69 0.57-12.7 0.21
Diabetes mellitus 0.28 0.09-0.85 0.02
Hypertension 0.86 0.15-4.87 0.87
Chronic renal insufficiency 7.78 1.36-44.6 0.02
Lesions dilated 1.85 1.04-3.31 0.04
